(VIANEWS) – MEDISTIM (MEDI.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| MEDISTIM (MEDI.OL) | kr171.00 | 2.65% | 24.73% |
| EUROFINS SCIENT. (ERF.PA) | €59.08 | 1.04% | 6.16% |
| UCB (UCB.BR) | €142.95 | 0.95% | 3.8% |
| VIRBAC (VIRP.PA) | €346.00 | 0.37% | 13.84% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. MEDISTIM (MEDI.OL)
2.65% Forward Dividend Yield and 24.73% Return On Equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardiac and vascular surgery in the United States, Europe, Asia, and internationally. The company offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and TTFM in a single system for vascular surgery; MiraQ Ultimate that combines TTFM and ultrasound imaging in a single system for cardiac, vascular, and transplant surgery; and imaging probes for intraoperative use. It also provides QuickFit TTFM probes, which is designed to hold the vessel and ensure precise measurements on various types of vessel grafts; Vascular TTFM probes for locking slide mechanism designed to secure the vessel while minimizing the manipulation of fragile or calcified vessels; and Doppler probes that are used to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, the company distributes and sells third party medical equipment. Medistim ASA was founded in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr5.61.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 30.48. Meaning, the purchaser of the share is investing kr30.48 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.73%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MEDISTIM’s stock is considered to be oversold (<=20).
Volume
Today’s last reported volume for MEDISTIM is 1247 which is 82.01% below its average volume of 6935.
Revenue Growth
Year-on-year quarterly revenue growth grew by 3.5%, now sitting on 525.64M for the twelve trailing months.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Apr 25, 2024, the estimated forward annual dividend rate is 4.5 and the estimated forward annual dividend yield is 2.65%.
More news about MEDISTIM.
2. EUROFINS SCIENT. (ERF.PA)
1.04% Forward Dividend Yield and 6.16% Return On Equity
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of various analytical methods and tests to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, healthcare and cosmetics, and food supplements; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include sustainability, expert services and regulatory, consumer research and sensory evaluation, audits, testing, certifications and approvals, inspections, and training courses for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, training and consulting; food irradiation and labelling, heavy metals, carbohydrates, radioactivity, nutritional analysis, microbiolody, and testing for persistent organic pollutants, veterinary drug residue, dioxins and organic contaminants, pesticides, mycotoxins, and vitamins, as well as analyses for genetic modifications. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and other services. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
Earnings Per Share
As for profitability, EUROFINS SCIENT. has a trailing twelve months EPS of €1.57.
PE Ratio
EUROFINS SCIENT. has a trailing twelve months price to earnings ratio of 37.63. Meaning, the purchaser of the share is investing €37.63 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.16%.
More news about EUROFINS SCIENT..
3. UCB (UCB.BR)
0.95% Forward Dividend Yield and 3.8% Return On Equity
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Earnings Per Share
As for profitability, UCB has a trailing twelve months EPS of €1.75.
PE Ratio
UCB has a trailing twelve months price to earnings ratio of 81.69. Meaning, the purchaser of the share is investing €81.69 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.8%.
Volume
Today’s last reported volume for UCB is 66055 which is 76.35% below its average volume of 279314.
Sales Growth
UCB’s sales growth for the current quarter is 7.3%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, UCB’s stock is considered to be oversold (<=20).
Yearly Top and Bottom Value
UCB’s stock is valued at €142.95 at 07:30 EST, below its 52-week high of €144.60 and way above its 52-week low of €65.40.
More news about UCB.
4. VIRBAC (VIRP.PA)
0.37% Forward Dividend Yield and 13.84% Return On Equity
Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.
Earnings Per Share
As for profitability, VIRBAC has a trailing twelve months EPS of €14.12.
PE Ratio
VIRBAC has a trailing twelve months price to earnings ratio of 24.5. Meaning, the purchaser of the share is investing €24.5 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.84%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jun 25, 2024, the estimated forward annual dividend rate is 1.32 and the estimated forward annual dividend yield is 0.37%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 6.1%, now sitting on 1.25B for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, VIRBAC’s stock is considered to be oversold (<=20).
Volatility
VIRBAC’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.05%, a negative 0.05%, and a positive 1.55%.
VIRBAC’s highest amplitude of average volatility was 1.43% (last week), 1.76% (last month), and 1.55% (last quarter).
More news about VIRBAC.
